Author:
Chlup Rudolf,Zálešáková Hana,Gottwaldová Jiřina,Trefil Michal,Zapletalová Jana,Kaňa Richard,Hanáčková Lada,Bretšnajdrová Milena,Falt Přemysl,Polzerová Zdenka
Abstract
The purpose of this chapter was (1) to identify the frequency of employing different kinds of medication (beta-stimulators, metformin, gliflozins, incretins and/or insulins, pioglitazone, statins, fibrates), (2) to assess global metabolic effectiveness of this medication in a walk-in diabetes center, and (3) to estimate frequency of HbA1c measurements in people admitted to hospital. Methods: In 200 people with T2D (age 24–95 y, 105 men) HbA1c, BM, BMI, blood pressure [BP], lipoproteins HDL, LDL, TAG, eGFR, proteinuria were assessed. Individual observation periods took in the range of 0.5–8.8 years. Student’s t-test, Wilcoxon signed-rank test with Bonferroni correction and Spearman analysis were used to asses changes between the first and the last visit. P < 0.05 was considered as significant. In conclusion, reduction of HbA1c from start values of 52.6 (31.5–173.0) to 46.6 (31.5–116.6) mmol/mol along with reduction of BMI from 26.7 (16.0–45.3) to 25.4 (15.4–42.2) kg/m2 (P < 0.0001) and correlation of delta HbA1c with delta BMI (r = 0.209, p = 0.003) confirmed global metabolic effectiveness of medication used in the walk-in diabetes center where the HbA1c was estimated 2–3 times per year in each subject whereas in hospital wards mostly once in up to 15% of admitted T2D patients.
Reference62 articles.
1. Chlup R, Kaňa R, Hanáčková L, Zálešáková H, Doubravová B. Pathophysiologic approach to type 2 diabetes management: One centre experience 1980–2020. Available from:
2. Friedecký B, Kratochvíla J, Springer D, Prázný M, Pelikánová T, Zima T, et al. Diabetes mellitus – Laboratorní diagnostika a sledování stavu pacientů. Diabetes mellitus – Laboratory diagnostics and observation of patients’ condition. Klinická biochemie a metabolismus. 2019;(48):32-47
3. Hanas R, John G, On behalf of the International HbA1c Consensus Committee. 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. . 2010;:1903-1904
4. Chlup R, Doubravová B, Bartek J, Zapletalová J, Krystyník O, Procházka V. Effective assessment of diabetes control using personal glucometers (Contourlink, Bayer, Germany; Calla, Wellion, Austria; Linus, Agamatrix, USA). Disease Markers. 2013;(6):895-905
5. Aronson R, Reznik Y, Conget I, et al, for the OpT2mise Study Group. Sustained efficacy of insulin pump therapy compared with multiple injections in type 2 diabetes: 12-month data from the OpT2mise randomised trial. Diabetes, Obesity and Metabolism. 2016;(5):500–507